Bottom line
What is IMORX's expense ratio?
IMORX's expense ratio is 1.47%, or about $147 a year on every $10,000 invested. That is more expensive than 87% of mid-cap funds we track (median 0.88%). It has no front-end sales load. Its expense ratio includes a 0.5% 12b-1 marketing fee.
Updated Sep 25, 2026
IMORX fee table
| Net expense ratio | 1.47% |
|---|---|
| Gross expense ratio | 1.55% |
| Management fee | 0.84% |
| 12b-1 (distribution) fee | 0.5% |
| Other expenses | 0.21% |
| Fee waiver / reimbursement | -0.08% |
| Max front-end sales load | 0% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Sep 25, 2026
What IMORX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| IMORX | $150 | $482 | $837 | $1,839 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.47% expense ratio costs roughly $78,200 in lost growth, versus about $49,300 for the median mid-cap fund (0.88%).
Cheaper alternatives to IMORX
These funds have a similar portfolio (by top-holdings overlap) and a lower expense ratio. Savings are per $10,000 invested.
| Fund | Expense ratio | Saves per year | Saves over 20 yrs* | Overlap |
|---|---|---|---|---|
| IWP iShares | 0.23% | $124 | $6,452 | 52% |
*Difference in ending value of $10,000 after 20 years at a 6% gross annual return, net of each fund's expense ratio.